Effects of Soy Consumption on Metabolic Parameters in Patients with Metabolic Syndrome: A Systematic Review and Meta-Analysis

Abstract

Functional foods like soy have unique effects on health status. Although various dietary modifications have been recommended to ameliorate features of metabolic syndrome (MetS), no meta-analysis has summarized the effect of soy consumption in patients with MetS. PubMed, ISI Web of Science, and Scopus were searched for relevant articles until Jun 2020, resulting in six relevant publications that were included in our meta-analysis. Combining a total of 9 comparisons suggested a significant decrease in serum levels of triglyceride (WMD: -0.29; 95 CI: -0.49, -0.09 mg/dL), total cholesterol (WMD: -1.46; 95 CI: -1.70, -1.22 mg/dL), LDL-C (WMD: -0.73; 95 CI: -0.93, -0.52 mg/dL) and no change in serum HDL-c levels. Combining a total of 7 effect sizes examining soy effects on glycemic parameters indicated that subjects who consumed soy products had lower levels of fasting blood sugar (WMD: -0.90; 95 CI: -1.12, -0.68 mg/dL), insulin (WMD: -1.06; 95 CI: -1.29, -0.84 pmol/ L) and HOMA-IR (WMD: -1.08; 95 CI: -1.31, -0.85) compared with those in the control group. Soy consumption could not significantly change anthropometric measures and blood pressure. Consuming soy products in patients with MetS effectively improved lipid profile and glycemic parameters independent of affecting anthropometric measures.